SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM)
| Autor: | Wasfa Aijaz, Saima Ghaus, Erum Sohail, Tasnim Ahsan |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Efficacy 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Hypoglycemia 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Glycemic control Weight loss Internal medicine Diabetes mellitus SGLT 2 Inhibitors medicine Empagliflozin Dapagliflozin Glycemic business.industry General Medicine medicine.disease Blood pressure chemistry Original Article medicine.symptom Safety business |
| Zdroj: | Pakistan Journal of Medical Sciences |
| ISSN: | 1682-024X |
| Popis: | Background & Objective: Sodium glucose co-transporter-2 inhibitors (SGLT 2 inhibitors) are newer anti-hyperglycemic agents, which improve glycemic control independent of insulin secretion with a low risk of hypoglycemia. This study aimed to assess the efficacy of SGLT 2 inhibitors in terms of glycemic control, weight reduction and safety profile in our patients with type 2 Diabetes (T2D). Methods: This is a prospective analysis, conducted at Medicell Institute of Diabetes, Endocrinology and Metabolism (MIDEM), Karachi Pakistan from January 2018 till July 2019. This study included patients with T2D, who were treated with SGLT 2 inhibitors add on to other anti-diabetic drugs. Baseline and follow up weight, BMI, HbA1c, blood pressure (BP), renal function and side effect profile was assessed. Results: Study included 140 patients; 53% females and 47% males. Mean Age was 55.6 ± 10.3 years. Mean weight at baseline was 81.5 ±16.5 kg. Mean duration of T2D was 10.3 ± 6.75 years, with a mean HbA1C at baseline of 9.1± 1.6%. Follow up data was available for 90 patients at the time of analysis. HbA1C improved considerably to 7.6± 0.9 (P< 0.001) and mean weight reduced to 78.5 ± 16.1 kg (P≤0.003), at first follow-up. Conclusion: Dapagliflozin and Empagliflozin offer a significant additional drug in improving glycemic control with the additional advantage of weight loss and hypoglycemia safety. doi: https://doi.org/10.12669/pjms.37.1.2701 How to cite this:Sohail E, Ahsan T, Ghaus S, Aijaz W. SGLT 2 Inhibitors; glycemic control, weight loss and safety profile in patients with type 2 Diabetes, at Medicell Institute (MIDEM). Pak J Med Sci. 2021;37(1):87-92. doi: https://doi.org/10.12669/pjms.37.1.2701 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|